Drugs / Dacarbazine
Dacarbazine
also known as
DTIC · Dacarbazine - DTIC · Biocarbazine r · dacarbacine · Dacarbasine · Dacarbazina · Dacarbazine (DTIC)-Dome · Dacarbazinum · +7 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed classic Hodgkin lymphoma 1 milestone | |||||
| Filed | US (FDA) | Opdivo | classic Hodgkin lymphoma | 2025-12-11 | “FDA has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo ® (nivolumab) in combination with doxorubicin, vinblastine and...” bms.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Label expansion | US (FDA) | DTIC-DOME | — | 1981-04-29 | fda.gov ↗ |
| Approved | US (FDA) | DTIC-DOME | — | 1975-05-27 | fda.gov ↗ |
Trials 137 · started per year
today
US approved 1975
1
3
3
6
3
5
4
2
4
6
3
6
5
7
4
7
4
7
7
2
1
1
9
3
6
4
3
4
4
4
4
3
19741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00600496 | Dec 2007 → Aug 2010 | breast cancer, colonic neoplasm, colorectal cancer, kidney cancer +2 | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00542893 | Apr 2006 → Sep 2007 | melanoma | Genta Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00412581 | Sep 2005 → Mar 2008 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00580320 | Sep 2004 → Oct 2009 | carcinoid tumor, melanoma, parathyroid gland carcinoma, small cell lung carcinoma +1 | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/213 trials · 1 met primary | ||||||
| Phase 1/2 | NCT03331341 | Jan 2019 → Dec 2023 | classic Hodgkin lymphoma | University of Washington | Completed | Met primary |
| Phase 1/2 | NCT03277924 | May 2017 → Jun 2024 | bone sarcoma, soft tissue sarcoma | Spanish Group for Research in Sarcomas | Completed | No outcome recorded |
| Phase 1/2 | NCT02076646 | Jul 2013 → May 2016 | metastatic melanoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01771107 | Mar 2013 → Oct 2021 | HIV infectious disease, classic Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01614301 | May 2012 → May 2014 | melanoma | University of Regensburg | Unknown | No outcome recorded |
| Phase 1/2 | NCT01133977 | Apr 2010 → Jun 2014 | melanoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00597038 | Nov 2007 → Sep 2011 | metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00615160 | Dec 2006 → Sep 2008 | melanoma | Michael Weichenthal | Terminated | No outcome recorded |
| Phase 1/2 | NCT00496223 | Sep 2006 → Jun 2007 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00327600 | Jul 2005 → Jan 2007 | melanoma | AmpliMed Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00246012 | May 2005 → Jun 2008 | melanoma | Centocor, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00354523 | Dec 2004 → Nov 2006 | thyroid cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00023738 | Aug 2001 → Oct 2003 | sarcoma | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 275 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT07847359 | Oct 2026 → Dec 2028 expected | cutaneous melanoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07551583 | Aug 2026 → Dec 2030 expected | Hodgkins lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07275216 | Jul 2026 → Oct 2029 expected | classic Hodgkin lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06835049 | Oct 2025 → Mar 2028 expected | soft tissue sarcoma | Swiss Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07002216 | Jul 2025 → Jul 2030 expected | Hodgkins lymphoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT06984146 | Apr 2025 → Jan 2028 expected | classic Hodgkin lymphoma | National Medical Research Radiological Centre of the Ministry of Health of Russia | Recruiting | No outcome recorded |
| Phase 2 | NCT06745076 | Mar 2025 → Jan 2032 expected | classic Hodgkin lymphoma | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT07234487 | Oct 2024 → Oct 2029 expected | classic Hodgkin lymphoma | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06377566 | Apr 2024 → Apr 2027 expected | Hodgkins lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06164275 | Feb 2024 → Jul 2025 overdue | classic Hodgkin lymphoma | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05922904 | Dec 2023 → Oct 2027 expected | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05900765 | Jun 2023 → Jun 2025 | classic Hodgkin lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05466474 | Dec 2022 → Apr 2024 | melanoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06201507 | Oct 2022 → Dec 2024 | classic Hodgkin lymphoma | Beijing Children's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05404945 | Jul 2022 → Oct 2027 expected | classic Hodgkin lymphoma | University of Virginia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05008224 | Oct 2021 → Oct 2023 | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04535271 | Sep 2021 → Sep 2028 expected | leiomyosarcoma | Sarcoma Oncology Research Center, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT04727242 | Jan 2021 → Jan 2026 | leiomyosarcoma | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT04733183 | Aug 2020 → Dec 2025 overdue | soft tissue sarcoma | Philogen S.p.A. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04225390 | Jan 2020 → Jan 2026 | — | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04067037 | Aug 2019 → Jan 2026 overdue | classic Hodgkin lymphoma | Henan Cancer Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03517137 | Aug 2019 → Aug 2023 overdue | Hodgkins lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03646123 | Jan 2019 → Nov 2022 | classic Hodgkin lymphoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03755804 | Dec 2018 → Jan 2027 expected | classic Hodgkin lymphoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03712202 | Nov 2018 → Dec 2024 overdue | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03023124 | Mar 2018 → Dec 2024 | solitary fibrous tumor | Italian Sarcoma Group | Completed | No outcome recorded |
| Phase 2 | NCT03226249 | Nov 2017 → May 2019 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, lymphocytic-histiocytic predominance, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | Northwestern University | Unknown | No outcome recorded |
| Phase 2 | NCT03233347 | Oct 2017 → Jul 2025 overdue | classic Hodgkin lymphoma | Academic and Community Cancer Research United | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03279601 | Sep 2017 → Sep 2019 | neuroendocrine neoplasm | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03004833 | Feb 2017 → Aug 2022 | classic Hodgkin lymphoma | University of Cologne | Completed | Mixed |
| Phase 2 | NCT02190838 | Apr 2014 → Dec 2015 | melanoma | N.N. Petrov National Medical Research Center of Oncology | Terminated | Missed primary |
| Phase 2 | NCT07671495 | Jan 2014 → Dec 2017 | cutaneous melanoma | MIPO Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01835145 | Jul 2013 → Oct 2016 | uveal melanoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT01390584 | May 2013 → Apr 2015 | lymphoma | ECOG-ACRIN Cancer Research Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01845675 | Apr 2013 → Nov 2016 | pancreatic neuroendocrine tumor | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01704287 | Nov 2012 → Nov 2015 | melanoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 2 | NCT01716806 | Oct 2012 → Apr 2023 | classic Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Seagen Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01681212 | Oct 2012 → May 2014 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01692691 | Aug 2012 → Oct 2014 | metastatic melanoma | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT02247869 | Feb 2012 → Jun 2015 | Hodgkins lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 2 | NCT01476410 | Nov 2011 → Apr 2017 | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, adult nodular lymphocyte predominant Hodgkin lymphoma, nodular sclerosis classical Hodgkin lymphoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT01376713 | Jun 2011 → Jan 2015 | metastatic melanoma | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT01523847 | Nov 2010 → Oct 2013 | Hodgkins lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 2 | NCT01118026 | Sep 2010 → Sep 2020 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01542255 | Jun 2010 → Jan 2013 | metastatic melanoma | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01143402 | Jun 2010 → May 2016 | iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension, small size posterior uveal melanoma | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 2 | NCT01132807 | May 2010 → Feb 2016 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01100528 | Nov 2009 → Jul 2015 | iris melanoma, medium/large size posterior uveal melanoma, small size posterior uveal melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00885534 | Apr 2009 → Oct 2013 | melanoma, skin cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00802880 | Mar 2009 → Jan 2015 | sarcoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00837148 | Feb 2009 → Nov 2013 | leiomyosarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00794235 | Dec 2008 → Nov 2009 | melanoma | University of Zurich | Completed | No outcome recorded |
| Phase 2 | NCT00813449 | Aug 2008 → Aug 2010 | melanoma | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT01055522 | Jun 2008 → Feb 2013 | metastatic melanoma | Philogen S.p.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00795613 | Jun 2008 → Nov 2014 | Hodgkins lymphoma | Ospedale Santa Croce-Carle Cuneo | Unknown | No outcome recorded |
| Phase 2 | NCT00553618 | Aug 2007 → Aug 2025 overdue | metastatic melanoma | University of Louisville | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01164007 | Jun 2006 → May 2012 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00369681 | May 2006 → Oct 2014 | lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00099970 | Dec 2004 → Mar 2006 | melanoma, metastatic neoplasm | PDL BioPharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00089544 | Jun 2004 → Sep 2011 | soft tissue sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01468740 | Mar 2004 → Feb 2012 | Hodgkins lymphoma | Harlachinger Krebshilfe e.V. | Unknown | No outcome recorded |
| Phase 2 | NCT00070642 | Dec 2003 → Dec 2005 | melanoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00066196 | Aug 2003 → Apr 2007 | metastatic melanoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00416832 | Nov 2002 → Dec 2005 | lymphoma | Christine Mauz-Körholz | Completed | No outcome recorded |
| Phase 2 | NCT00033644 | Mar 2002 → Oct 2005 | sarcoma | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Phase 2 | NCT00504504 | Mar 2001 → Mar 2012 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00025064 | Jan 2000 → ? | lymphoma | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 2 | NCT00004010 | Oct 1999 → Oct 2003 | lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00004141 | Aug 1998 → Jan 2003 | cutaneous melanoma | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00017225 | May 1997 → Feb 2002 | neuroblastoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Completed | No outcome recorded |
| Phase 2 | NCT00002791 | Feb 1997 → May 2002 | sarcoma | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002669 | Jun 1995 → Aug 2002 | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00006200 | — | melanoma | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase 2 | NCT00000626 | ? → Feb 1999 | HIV infectious disease, Hodgkins lymphoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT06563245 | Sep 2024 → Nov 2029 expected | classic Hodgkin lymphoma | Children's Cancer Group, China | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00784537 | Sep 2008 → Jan 2015 | Hodgkins lymphoma | Fondazione Italiana Linfomi - ETS | Completed | Missed primary |
| Phase 334 trials · 3 met primary · 6 missed | ||||||
| Phase 3 | NCT05675410 | May 2023 → Apr 2031 expected | Hodgkins lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT05868707 | Mar 2023 → Mar 2026 overdue | melanoma | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04685616 | Apr 2022 → Sep 2030 expected | Hodgkins lymphoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT04307277 | Oct 2020 → Oct 2032 expected | soft tissue sarcoma | Institut Claudius Regaud | Recruiting | No outcome recorded |
| Phase 3 | NCT04638790 | Feb 2020 → Dec 2026 expected | classic Hodgkin lymphoma | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Recruiting | No outcome recorded |
| Phase 3 | NCT04221035 | Nov 2019 → Nov 2026 expected | neuroblastoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT03805022 | Feb 2019 → Dec 2026 expected | soft tissue sarcoma | Institut Bergonié | Recruiting | No outcome recorded |
| Phase 3 | NCT03016819 | Aug 2017 → Dec 2027 expected | alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT03159897 | Aug 2017 → Nov 2021 | classic Hodgkin lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 3 | NCT02661503 | Jul 2016 → Dec 2022 | classic Hodgkin lymphoma | University of Cologne | Unknown | Met primary |
| Phase 3 | NCT02545075 | Oct 2015 → Apr 2019 | melanoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT01652261 | May 2013 → Oct 2014 | Hodgkins lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01710176 | Jun 2011 → Jun 2024 | soft tissue sarcoma | Italian Sarcoma Group | Completed | Missed primary |
| Phase 3 | NCT01358747 | May 2011 → ? | Hodgkins lymphoma | Centre Hospitalier Universitaire Dijon | Completed | Met primary |
| Phase 3 | NCT01245062 | Nov 2010 → Oct 2011 | melanoma | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00920153 | May 2008 → Mar 2016 | lymphoma | French Innovative Leukemia Organisation | Terminated | No outcome recorded |
| Phase 3 | NCT00433459 | Jan 2007 → Jan 2013 | lymphoma | Christine Mauz-Körholz | Completed | Mixed |
| Phase 3 | NCT00433433 | Oct 2006 → Dec 2011 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | Missed primary |
| Phase 3 | NCT00410631 | Oct 2004 → Dec 2010 | neuroblastoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| Phase 3 | NCT00072124 | Sep 2003 → May 2005 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00041210 | Oct 2001 → ? | lymphoma | Mount Vernon Cancer Centre at Mount Vernon Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00006237 | Aug 2000 → Jul 2012 | cutaneous melanoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00016263 | Jul 2000 → Dec 2004 | cutaneous melanoma | Genta Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT00005090 | Apr 2000 → May 2005 | lymphoma | SWOG Cancer Research Network | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00003389 | Jun 1999 → Sep 2011 | lymphoma | Eastern Cooperative Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00005584 | Oct 1998 → May 2004 overdue | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | Mixed |
| Phase 3 | NCT00003647 | Jul 1998 → Sep 2002 | melanoma | Vical | Completed | No outcome recorded |
| Phase 3 | NCT00003421 | Jun 1998 → Nov 2005 | lymphoma | Medical Research Council | Completed | Missed primary |
| Phase 3 | NCT00264953 | May 1998 → Jan 2003 | Hodgkins lymphoma | University of Cologne | Completed | Mixed |
| Phase 3 | NCT00265018 | May 1998 → Jan 2003 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00003027 | Nov 1997 → Jul 2007 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002882 | Nov 1995 → Aug 2003 | melanoma, skin cancer | M.D. Anderson Cancer Center | Completed | Missed primary |
| Phase 3 | NCT00970385 | Jan 1995 → Dec 2002 | peripheral T-cell lymphoma, not otherwise specified | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 3 | NCT00002802 | Jul 1990 → Sep 2003 | neuroblastoma | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03500133 | Oct 2017 → Oct 2027 expected | Hodgkins lymphoma | Hospital JP Garrahan | Recruiting | No outcome recorded |
| Phase 4 | NCT00226473 | Sep 2001 → Sep 2005 | metastatic melanoma | Dermatologic Cooperative Oncology Group | Unknown | No outcome recorded |
| Phase 4 | NCT00188149 | May 2000 → Dec 2007 | Hodgkins lymphoma | University Hospital Carl Gustav Carus | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT01868451 | May 2013 → Jun 2026 | Hodgkins lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01578967 | Apr 2012 → Aug 2016 | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT00901303 | Oct 2008 → Jun 2010 | Hodgkins lymphoma | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00526318 | Jan 2007 → Dec 2016 | neuroblastoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Unknown | No outcome recorded |
| — | NCT00070343 | Aug 2003 → ? | cutaneous melanoma | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| — | NCT00416377 | — | lymphoma | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Comparator or background therapy91 trials | ||||||
| Phase 1 | NCT03761095 Background | Mar 2019 → Feb 2024 | leiomyosarcoma | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01056679 Background | Apr 2010 → Apr 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 1 | NCT01060904 Background | Jan 2010 → Sep 2012 | Hodgkins lymphoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00796991 Comparator | Feb → Nov 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00498979 Background | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00516802 Background | Jan 2007 → Jan 2009 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02979522 Background | Sep 2017 → May 2020 overdue | classic Hodgkin lymphoma | Takeda | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03033914 Background | Jan 2017 → Jan 2027 expected | classic Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07400302 Background | Apr 2026 → Sep 2029 expected | mucosal melanoma | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 2 | NCT07406724 Comparator | Feb 2026 → Dec 2027 expected | melanoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07310784 Comparator | Dec 2025 → Dec 2027 expected | melanoma | Suzhou BlueHorse Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06703398 Comparator | Dec 2024 → Jul 2026 overdue | melanoma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05627115 Background | Mar 2024 → Oct 2028 expected | Hodgkins lymphoma | University College, London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05772624 Background | Feb 2023 → Mar 2024 | — | Hospital Universitario Dr. Jose E. Gonzalez | Unknown | No outcome recorded |
| Phase 2 | NCT05253495 Background | Feb 2022 → Dec 2027 expected | Hodgkins lymphoma, non-Hodgkin lymphoma | New York Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT03407144 Background | Apr 2018 → Feb 2027 expected | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03527628 Background | Jan 2018 → Jan 2021 | classic Hodgkin lymphoma | King Abdullah International Medical Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT03070392 Comparator | Oct 2017 → Oct 2020 | uveal melanoma | Immunocore Ltd | Completed | Met primary |
| Phase 2 | NCT04200040 Comparator | Aug 2017 → Dec 2022 | cutaneous melanoma | OrienGene Biotechnology Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02505269 Background | Aug 2015 → Jun 2019 | Hodgkins lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02292979 Background | Mar 2015 → Dec 2016 | Hodgkins lymphoma | The Lymphoma Academic Research Organisation | Completed | Met primary |
| Phase 2 | NCT02181738 Background | Aug 2014 → Aug 2017 | Hodgkins lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01920932 Background | Aug 2013 → Nov 2020 overdue | Hodgkins lymphoma | St. Jude Children's Research Hospital | Active not recruiting | Met primary |
| Phase 2 | NCT02275598 Background | Apr → Nov 2013 | Hodgkins lymphoma | University of Modena and Reggio Emilia | Unknown | No outcome recorded |
| Phase 2 | NCT01705392 Comparator | Jan 2013 → Feb 2017 | metastatic melanoma | Haukeland University Hospital | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01693068 Comparator | Dec 2012 → Jul 2015 | cutaneous melanoma | EMD Serono | Completed | Met primary |
| Phase 2 | NCT01569204 Comparator | Oct 2012 → Mar 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT01534078 Background | Mar 2012 → Jan 2015 | Hodgkins lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00797472 Comparator | Jul 2011 → Apr 2014 | Hodgkins lymphoma | American Scitech International | Unknown | No outcome recorded |
| Phase 2 | NCT01551459 Comparator | Oct 2010 → Sep 2017 | uveal melanoma | The Clatterbridge Cancer Centre NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT01152788 Comparator | Aug 2010 → Nov 2014 | melanoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01028222 Comparator | Jun 2010 → Dec 2014 | melanoma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT00991250 Comparator | Oct 2009 → Sep 2011 | melanoma | SentoClone AB | Unknown | No outcome recorded |
| Phase 2 | NCT00936221 Comparator | Jul 2009 → Nov 2011 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00822120 Comparator | Jul 2009 → Apr 2016 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT05898451 Background | Jun 2009 → Nov 2011 | cancer | Refnot-Pharm Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00849875 Background | May 2009 → Nov 2014 | melanoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00654732 Background | Mar 2008 → Sep 2018 | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00533702 Comparator | Nov 2007 → May 2011 | metastatic melanoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00308607 Background | Aug 2005 → Dec 2008 | metastatic melanoma | University of Turku | Completed | No outcome recorded |
| Phase 2 | NCT00130442 Comparator | Jun 2005 → Oct 2010 | melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00492297 Background | Apr 2005 → Jun 2008 | melanoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00110994 Background | Apr 2005 → Oct 2006 | cancer, melanoma | Bayer | Completed | Missed primary |
| Phase 2 | NCT00911443 Background | Jul 2002 → Sep 2007 | melanoma | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01404936 Background | Jul 1996 → Dec 2011 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT06624644 Comparator | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05987332 Comparator | Oct 2023 → Jan 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | Met primary |
| Phase 2/3 | NCT05269355 Background | May 2022 → Jun 2024 | leiomyosarcoma | PTC Therapeutics | Terminated | Met primary Stop: Business |
| Phase 3 | NCT06743126 Comparator | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06264180 Comparator | Jul 2024 → Sep 2030 expected | melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06346067 Comparator | Apr 2024 → Apr 2028 expected | melanoma | Erasca, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06008106 Comparator | Nov 2023 → Sep 2027 expected | melanoma | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03907488 Background | Aug 2019 → Mar 2024 overdue | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT03430297 Comparator | Feb 2018 → Jul 2023 | metastatic melanoma | Shanghai Junshi Bioscience Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02684708 Comparator | Oct 2015 → Oct 2024 | classic Hodgkin lymphoma | University of Giessen | Completed | No outcome recorded |
| Phase 3 | NCT02288897 Comparator | Apr 2015 → Apr 2019 | cutaneous melanoma | Provectus Biopharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01974752 Background | Apr 2014 → May 2015 | metastatic malignant neoplasm, uveal melanoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT02049905 Comparator | Jan 2014 → May 2017 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01763164 Comparator | Jul 2013 → Dec 2015 | cutaneous melanoma | Pfizer | Completed | Met primary |
| Phase 3 | NCT01721772 Comparator | Jan 2013 → Jun 2014 | melanoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT01721746 Comparator | Dec 2012 → Feb 2016 | metastatic melanoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT01712490 Background | Nov 2012 → Apr 2017 | Hodgkins lymphoma | Takeda | Completed | Met primary |
| Phase 3 | NCT01692678 Comparator | Aug 2012 → Oct 2016 | liposarcoma | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01356680 Background | Jan 2012 → Mar 2020 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00816959 Comparator | Jul 2011 → Apr 2014 | Hodgkins lymphoma | American Scitech International | Unknown | No outcome recorded |
| Phase 3 | NCT01343277 Comparator | Jun 2011 → Jan 2015 | — | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 3 | NCT01327885 Comparator | Mar 2011 → Jan 2015 | soft tissue sarcoma | Eisai Inc. | Completed | Met primary |
| Phase 3 | NCT01280565 Comparator | Jan 2011 → Aug 2019 | metastatic melanoma | AB Science | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01227889 Comparator | Dec 2010 → Dec 2011 | cancer | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01006980 Comparator | Jan → Dec 2010 | melanoma | Hoffmann-La Roche | Completed | Met primary |
| Phase 3 | NCT00736320 Background | Nov 2009 → Sep 2018 | Hodgkins lymphoma | University of Cologne | Unknown | No outcome recorded |
| Phase 3 | NCT00864253 Comparator | Apr 2009 → Jun 2012 | melanoma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT00779714 Comparator | Oct 2008 → Oct 2012 | melanoma | University of Wuerzburg | Unknown | No outcome recorded |
| Phase 3 | NCT00678327 Comparator | Aug 2008 → Jan 2016 | lymphoma | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT00518895 Background | Jul 2007 → May 2011 | melanoma | Genta Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT00395070 Comparator | Oct 2006 → Mar 2012 | metastatic melanoma | Vical | Completed | No outcome recorded |
| Phase 3 | NCT00324155 Background | Aug 2006 → Jan 2011 | melanoma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT00257205 Comparator | Mar 2006 → Aug 2010 | melanoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00091572 Comparator | Oct 2004 → Dec 2007 | melanoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00087776 Comparator | Dec 2002 → Oct 2007 | melanoma | American Regent, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00049595 Comparator | Aug 2002 → Jan 2010 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Missed primary |
| Phase 3 | NCT01359956 Background | Apr 2002 → Feb 2011 | melanoma | National Cancer Institute, Naples | Completed | Missed primary |
| Phase 3 | NCT00038558 Background | Nov 2001 → Feb 2004 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01251107 Comparator | Mar 2000 → Nov 2009 | Hodgkins lymphoma | Fondazione Michelangelo | Completed | No outcome recorded |
| Phase 3 | NCT00002561 Comparator | Jan 1994 → Aug 2011 | Hodgkins lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 4 | NCT06831370 Background | Aug 2024 → Mar 2028 expected | Hodgkins lymphoma | Takeda | Recruiting | No outcome recorded |
| Phase 4 | NCT02526823 Comparator | Aug 2015 → Dec 2019 | lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| — | NCT07171827 Background | Mar 2023 → Feb 2025 | classic Hodgkin lymphoma | Helwan University | Completed | No outcome recorded |
| — | NCT03217097 Comparator | Oct 2018 → Jan 2022 | neuroendocrine neoplasm | Hospices Civils de Lyon | Completed | Missed primary |
| — | NCT02800447 Comparator | Jun 2016 → Dec 2018 | Hodgkins lymphoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| — | NCT02797717 Background | Nov 2015 → Dec 2022 overdue | classic Hodgkin lymphoma | GALIA AVRAHAMI | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Bristol-Myers Squibb | Regulatory Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma bms.com ↗
This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the first immunotherapy-based regimen available in the European Union (EU) for newly diagnosed advanced cHL. |
| 2026-03-20 | Bristol-Myers Squibb | Regulatory Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) bms.com ↗
The U.S. Food and Drug Administration (FDA) granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL. |
| 2025-12-11 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma bms.com ↗ |
| 2024-12-05 | Pfizer | Results Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS pfizer.com ↗
In addition, updated two-year follow-up data from a Phase 2 study investigating the combination of ADCETRIS, nivolumab, doxorubicin, and dacarbazine in newly diagnosed early-stage classical Hodgkin lymphoma (cHL) will be presented highlighting promising efficacy and safety of this investigational novel combination. |
| 2024-06-01 | Pfizer | Results Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma pfizer.com ↗
The four-year analysis presented by the GHSG showed superior progression-free survival (PFS) and improved tolerability for patients compared to a current standard of care regimen used in Europe in this setting. |
| 2022-06-03 | PTC Therapeutics | Results Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study ptcbio.com ↗
The results from the dose escalation study which evaluated unesbulin in combination with dacarbazine (DTIC), will be presented on Saturday, June 4, during the Sarcoma Oral Abstract Session beginning at 1:15 p.m. CDT at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. |
| 2022-05-26 | Takeda | Results Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma takeda.com ↗
These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination should be considered a standard of care. |
| 2020-11-05 | Takeda | Results Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗
Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. |
| 2016-08-01 | Eisai Inc. | Results EISAI PRESENTS RESULTS OF ADDITIONAL ANALYSIS OF PHASE Ⅲ STUDY OF ANTICANCER AGENT HALAVEN® AT 14TH JSMO ANNUAL MEETING PLENARY SESSION eisai.com ↗
According to the results of these analyses, eribulin demonstrated a trend for extension in overall survival over dacarbazine in each subtype. |
| 2015-11-18 | Bristol-Myers Squibb | Results New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma bms.com ↗
In the trial, Opdivo continued to demonstrate superior overall survival versus dacarbazine with 57.7% of patients alive at two years compared to 26.7% of patients treated with dacarbazine. |
| 2015-07-22 | AstraZeneca | Results AstraZeneca provides update on selumetinib in uveal melanoma astrazeneca.com ↗
Wednesday, 22 July 2015 AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. |
| 2015-05-30 | Eisai Inc. | Results ANTICANCER AGENT HALAVEN® SHOWS SIGNIFICANT EXTENSION IN OVERALL SURVIVAL IN PHASE Ⅲ STUDY ON SOFT TISSUE SARCOMA Phase Ⅲ data to be presented in a Soft Tissue Sarcoma oral session at ASCO eisai.com ↗
In the study's primary endpoint of overall survival (OS), eribulin demonstrated a statistically significant extension in OS over the comparator treatment dacarbazine (eribulin median OS: 13.5 months vs dacarbazine median OS: 11.5 months, Hazard Ratio (HR) 0.768 [95% CI=0.618-0.954], p=0.017). |
| 2014-11-16 | Bristol-Myers Squibb | Results Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial bms.com ↗
Opdivo demonstrated superior overall survival vs. dacarbazine with a one-year survival rate of 73% vs. 42% and a 58% decrease in the risk of death (Hazard Ratio [HR] = 0.42, P < 0.0001) |
| 2014-09-29 | GlaxoSmithKline | Results GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma gsk.com ↗
45 per cent of patients treated with dabrafenib only, were alive at two years compared to 32 per cent of patients who began treatment with dacarbazine (DTIC). |
| 2014-06-24 | Bristol-Myers Squibb | Results Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early bms.com ↗ |
| 2013-06-10 | Eisai Inc. | Results EISAI CONFIRMS THERAPEUTIC EFFECTS OF LENVATINIB IN PATIENTS WITH MELANOMA IN STRATEGIC COLLABORATION WITH QUINTILES TO DEVELOP EISAI ANTICANCER COMPOUNDS eisai.com ↗
The results demonstrated a statistically significant 2.7-fold increase (p=0.0033) in progression-free survival (PFS) in patients given the combination of lenvatinib and dacarbazine versus dacarbazine alone (median PFS: 19.1 weeks versus 7.0 weeks respectively). |
| 2012-09-29 | Bristol-Myers Squibb | Results New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology) bms.com ↗
Long-term follow-up from this study demonstrated that treatment with YERVOY plus DTIC resulted in a four-year survival rate of 19.0% compared to 9.6% for DTIC alone. |
All press releases naming this drug 17 releases
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 230 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dacarbazine | “The "alkylating-based" group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or...” NCT03217097 ↗220“Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗ “Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks.” PMID 22663011 ↗ Jun 2012 “Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;” NCT02049905 ↗ “A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma” NCT00327600 ↗ “The other half (Group II) will receive a combination of intravenous Adriamycin, Bleomycin, Vinblastine and Dacarbazine every other week for 12 treatments.” NCT00797472 ↗ “ABVD was given every 28 days (doxorubicin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2 intravenously on days 1 and 15)” PMID 30658935 ↗ Jan 2019 “A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma” NCT00542893 ↗ “Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle.” NCT02275598 ↗ “Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)” NCT04307277 ↗ “BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine” NCT00188149 ↗ |
| Known as | Biocarbazine r | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | dacarbacine | “Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma” NCT00779714 ↗ |
| Known as | Dacarbasine | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dacarbazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dacarbazine (DTIC)-Dome | “Dacarbazine (DTIC)-Dome” NCT01133977 ↗ |
| Known as | Dacarbazine - DTIC | “Dacarbazine - DTIC” NCT07275216 ↗ |
| Known as | Dacarbazinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dacin (Dacarbazin).ATC-Code: L01AX04 | “Dacin (Dacarbazin).ATC-Code: L01AX04” NCT00794235 ↗ |
| Known as | Decarbazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dicarbazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | DTIC | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗24“Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.” NCT01055522 ↗ “A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma” NCT00327600 ↗ “This is a combination Phase I/II design that explores the toxicity and activity of a combination of sunitinib and Dacarbazine (DTIC) for metastatic melanoma.” NCT00496223 ↗ “Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma” NCT01152788 ↗ “Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.” NCT03033914 ↗ “Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma” NCT00779714 ↗ “Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients” NCT00553618 ↗ “Dacarbazine (DTIC) has been approved for treating metastatic melanoma in the 1970s” NCT00308607 ↗ “Dacarbazine (DTIC) has been approved for treating metastatic melanoma in the 1970s” NCT00813449 ↗ “Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks” NCT01227889 ↗ |
| Known as | DTIC (Dacarbazine) | “DTIC (Dacarbazine)” NCT00597038 ↗ |
| Known as | DTIC-Dome | “DTIC-Dome (Dacarbazine)” NCT00354523 ↗ |
| Known as | NCI C04717 | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | NSC-45388 | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells” NCT00654732 ↗ |
| Modality | Small molecule | — CHEMBL476 ↗ |
| Route | Intravenous | “Patients receive doxorubicin, bleomycin, vinblastine, and dacarbazine IV on days 1 and 15 (ABVD).” NCT00002561 ↗ |